SALT LAKE CITY, UT / ACCESSWIRE / August 13, 2024 / KindlyMD, Inc. (“KindlyMD” or the “Company”) (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, is pleased to announce that management is scheduled to participate in the following August 2024 conferences.
Sidoti Micro-Cap Virtual Conference
Presentation Date and Time: Wednesday, August 14th at 11:30 a.m. ET
Webcast: https://sidoti.zoom.us/webinar/register/WN_VkaugCtaSp-QPy2xNOfuqA
Summer 2024 Investor Summit Virtual Conference
Presentation Date and Time: Tuesday, August 20th at 12:30 p.m. ET
Webcast: https://investors.kindlymd.com/events-presentations
To schedule a one-on-one meeting with the Company’s management team, please contact your representative at Sidoti, Investor Summit Group, or email KCSA Strategic Communications at KindlyMD@KCSA.com.
About KindlyMD
KindlyMD™ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
For more information, please visit www.kindlymd.com.
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com
SOURCE: KindlyMD, Inc
View the original press release on accesswire.com
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…